Daniel P Judge

List of Publications by Year
in descending order

210 papers	27,293 citations	7551 77 h-index	5965 160 g-index
216 all docs	216 docs citations	216 times ranked	19051 citing authors

#	Article	IF	Citations
1	Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. Journal of Cardiovascular Translational Research, 2022, 15, 689-691.	1.1	2
2	Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2022, 327, 454.	3.8	28
3	ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist DeBakey Cardiovascular Journal, 2022, 18, 17-26.	0.5	26
4	The response to cardiac resynchronization therapy in <scp>LMNA</scp> cardiomyopathy. European Journal of Heart Failure, 2022, 24, 685-693.	2.9	7
5	How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary. Future Cardiology, 2022, , .	0.5	0
6	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2022, 43, e1-e9.	1.0	35
7	A pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populations. Implementation Science Communications, 2022, 3, 48.	0.8	8
8	Hypermobile <scp>Ehlersâ€Danlos</scp> syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. Developmental Dynamics, 2021, 250, 318-344.	0.8	53
9	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€ACT</scp>) and longâ€term extension study. European Journal of Heart Failure, 2021, 23, 277-285.	2.9	103
10	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	2.1	82
11	Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. American Heart Journal, 2021, 233, 122-131.	1.2	10
12	The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. Human Molecular Genetics, 2021, 29, 3504-3515.	1.4	9
13	Epidemiology of the inherited cardiomyopathies. Nature Reviews Cardiology, 2021, 18, 22-36.	6.1	117
14	Exercise triggers CAPN1-mediated AIF truncation, inducing myocyte cell death in arrhythmogenic cardiomyopathy. Science Translational Medicine, 2021, 13, .	5.8	46
15	Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy, 2021, Volume 15, 1225-1243.	2.0	29
16	Cadherin 2-Related Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003097.	1.6	21
17	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation, 2021, 143, 1852-1862.	1.6	65
18	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation, 2021, 144, 7-19.	1.6	213

#	Article	IF	Citations
19	International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. Circulation Genomic and Precision Medicine, 2021, 14, e003273.	1.6	112
20	Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTRâ€ACT. ESC Heart Failure, 2021, 8, 3875-3884.	1.4	18
21	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
22	Heart Failure as a Consequence of Genetic Cardiomyopathy. , 2020, , 322-332.e2.		0
23	SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung and Circulation, 2020, 29, 1241-1246.	0.2	12
24	Endomyocardial Biopsy Characterization of HeartÂFailure With Preserved EjectionÂFraction and Prevalence of Cardiac Amyloidosis. JACC: Heart Failure, 2020, 8, 712-724.	1.9	138
25	Influence of Panel Selection on Yield of Clinically Useful Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Families. Circulation Genomic and Precision Medicine, 2020, 13, 548-550.	1.6	4
26	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	1.6	70
27	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	1.3	55
28	FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy. Journal of Medical Genetics, 2020, 57, 254-257.	1.5	43
29	Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Journal of the American Heart Association, 2020, 9, e013695.	1.6	14
30	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. European Heart Journal, 2020, 41, 1414-1429.	1.0	239
31	Multivalvular Pulsus Alternans. Circulation: Heart Failure, 2020, 13, e007134.	1.6	0
32	Genetic Dilated Cardiomyopathy Due to TTN Variants Without Known Familial Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003082.	1.6	4
33	Cardiac Amyloidosis. , 2020, , 167-177.		0
34	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	1.2	170
35	Positive family history decreases diagnosis time by over 200%. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 17-17.	1.4	2
36	Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 166-167.	1.4	4

#	Article	IF	Citations
37	Tnni3k alleles influence ventricular mononuclear diploid cardiomyocyte frequency. PLoS Genetics, 2019, 15, e1008354.	1.5	28
38	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.3	135
39	Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circulation Genomic and Precision Medicine, 2019, 12, e002467.	1.6	38
40	Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. Circulation, 2019, 140, 1491-1505.	1.6	127
41	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure, 2019, 21, 955-964.	2.9	84
42	Genetic aetiologies should be considered in paediatric cases of acute heart failure presumed to be myocarditis. Cardiology in the Young, 2019, 29, 917-921.	0.4	11
43	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
44	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	1.6	96
45	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
46	Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005593.	2.1	17
47	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). Journal of Cardiovascular Electrophysiology, 2018, 29, 1004-1009.	0.8	15
48	Protein molecular modeling techniques investigating novel <scp>TAB</scp>2 variant R347X causing cardiomyopathy and congenital heart defects in multigenerational family. Molecular Genetics & Genomic Medicine, 2018, 6, 666-672.	0.6	19
49	Genetic Evaluation of Cardiomyopathyâ€"A Heart Failure Society of America Practice Guideline. Journal of Cardiac Failure, 2018, 24, 281-302.	0.7	280
50	Four-Chamber Intracardiac Thrombi Complicating Wild-Type TTR Amyloidosis. Case Reports in Cardiology, 2018, 2018, 1-4.	0.1	0
51	Cardiac Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics, 2018, 142, S72-S81.	1.0	77
52	Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002237.	1.6	11
53	Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 174-179.	1.4	69
54	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	1.1	2

#	Article	IF	Citations
55	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	13.9	1,558
56	Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2018, 20, 899-909.	1.1	172
57	Bringing Autopsies Into the Molecular Genetic Era. Circulation, 2018, 137, 2727-2729.	1.6	4
58	Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiology, 2017, 2, 293.	3.0	53
59	Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. Journal of Cardiac Failure, 2017, 23, 340-344.	0.7	12
60	Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. Journal of Heart and Lung Transplantation, 2017, 36, 380-385.	0.3	69
61	Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy. Cell Reports, 2017, 18, 571-582.	2.9	90
62	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovascular Research, 2017, 113, 102-111.	1.8	148
63	Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. Heart Rhythm, 2017, 14, 883-891.	0.3	47
64	Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. American Journal of Cardiology, 2017, 120, 111-117.	0.7	35
65	Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 92-95.	1.4	24
66	Giant Ring Mitochondria in a Patient With Heart Failure and Cerebral White Matter Disease Resulting From an MT-TL1 Mitochondrial Gene Mutation. Journal of Cardiac Failure, 2017, 23, 652-655.	0.7	3
67	Implantable Cardioverterâ€Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. Journal of the American Heart Association, 2017, 6, .	1.6	68
68	Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Annals of Neurology, 2017, 82, 44-56.	2.8	61
69	Inheritance Impacts Mitral Valve Insufficiency. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	0
70	Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovascular Research, 2017, 113, 1521-1531.	1.8	98
71	Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation, 2017, 136, e200-e231.	1.6	189
72	Arrhythmogenic Cardiomyopathy. Circulation Research, 2017, 121, 784-802.	2.0	294

#	Article	IF	Citations
73	Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation: Heart Failure, 2017, 10, .	1.6	53
74	Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 194-204.	1.4	83
75	Role of Genetic Testing in Inherited Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1153.	3.0	75
76	The Role of Genetics in Peripartum Cardiomyopathy. Journal of Cardiovascular Translational Research, 2017, 10, 437-445.	1.1	13
77	Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice. JCI Insight, 2017, 2, .	2.3	44
78	Abstract 24032: Exercise Instigates Apoptosis-inducing Factor Nuclear Translocation and Myocyte Death in Arrhythmogenic Cardiomyopathy. Circulation, 2017, 136, .	1.6	0
79	Central role for GSK3Î² in the pathogenesis of arrhythmogenic cardiomyopathy. JCI Insight, 2016, 1, .	2.3	127
80	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	1.2	338
81	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart, 2016, 102, 303-312.	1.2	50
82	GLA-Ring Opportunities and Challenges for Fabry Disease â^—. Journal of the American College of Cardiology, 2016, 68, 2564-2566.	1.2	0
83	Untangling Wild-Type TransthyretinÂAmyloidosis. Journal of the American College of Cardiology, 2016, 68, 1021-1023.	1.2	2
84	Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. Journal of Cardiac Failure, 2016, 22, 583-585.	0.7	28
85	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2016, 5, 1-25.	1.4	124
86	Characterizing the Molecular Pathology of Arrhythmogenic Cardiomyopathy in Patient Buccal Mucosa Cells. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003688.	2.1	35
87	Comprehensive Versus Targeted Genetic Testing in Children with Hypertrophic Cardiomyopathy. Pediatric Cardiology, 2016, 37, 845-851.	0.6	13
88	Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. Journal of Heart and Lung Transplantation, 2016, 35, 868-876.	0.3	76
89	Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Translational Research, 2016, 9, 87-89.	1.1	3
90	Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm, 2016, 13, 199-207.	0.3	76

#	Article	IF	Citations
91	Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. European Heart Journal, 2016, 37, 755-763.	1.0	68
92	Surgical correction of tricuspid regurgitation in patients with ARVD/C. HeartRhythm Case Reports, 2015, 1, 326-330.	0.2	2
93	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in the PediatricÂPopulation. JACC: Clinical Electrophysiology, 2015, 1, 551-560.	1.3	74
94	Association of Common Variations on Chromosome 4q25 and Left Atrial Volume in Patients with Atrial Fibrillation. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S21712.	0.6	32
95	Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities. Journal of Cardiovascular Development and Disease, 2015, 2, 48-65.	0.8	9
96	Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer. Case Reports in Oncological Medicine, 2015, 2015, 1-3.	0.2	4
97	A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. ELife, 2015, 4, .	2.8	87
98	Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2015, 12, 716-725.	0.3	101
99	Why Should Cardiologists Consider Genetic Testing for Hypertrophic Cardiomyopathy? â^—. JACC: Heart Failure, 2015, 3, 189-191.	1.9	0
100	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal, 2015, 36, 847-855.	1.0	338
101	Translating Cardiovascular Knowledge: A Global Health Perspective. Journal of Cardiovascular Translational Research, 2015, 8, 1-2.	1.1	1
102	Fluctuating creatinine in the cardiac unit. Clinica Chimica Acta, 2015, 447, 52-54.	0.5	10
103	Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. Journal of Cardiovascular Translational Research, 2015, 8, 264-268.	1.1	13
104	Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2015, 8, 117-127.	1.1	61
105	Tafamidis in Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 519-526.	1.6	110
106	Contemporary Cardiac Issues in Duchenne Muscular Dystrophy. Circulation, 2015, 131, 1590-1598.	1.6	240
107	Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circulation: Cardiovascular Genetics, 2015, 8, 437-446.	5.1	370
108	Further Evidence of Harm From Exercise inÂARVD/C. Journal of the American College of Cardiology, 2015, 65, 1451-1453.	1.2	1

#	Article	IF	Citations
109	Mitral valve diseaseâ€"morphology and mechanisms. Nature Reviews Cardiology, 2015, 12, 689-710.	6.1	281
110	Spectrum of Biventricular Involvement on CMR Among Carriers of ARVD/C-Associated Mutations. JACC: Cardiovascular Imaging, 2015, 8, 863-864.	2.3	25
111	Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine. Journal of Cardiovascular Translational Research, 2015, 8, 466-474.	1.1	4
112	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Failure Reviews, 2015, 20, 163-178.	1.7	178
113	The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. European Heart Journal, 2015, 36, 872-881.	1.0	56
114	Abstract 18850: A Report on Cardiomyopathy and Arrhythmia Incidence in a Duchenne Muscular Dystrophy Cohort. Circulation, 2015, 132, .	1.6	0
115	Cardiovascular Disease in Osteogenesis Imperfecta. , 2014, , 329-334.		1
116	Angiotensin IIâ€"dependent TGF-Î² signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 2014, 124, 448-460.	3.9	214
117	Sildenafil does not improve cardiomyopathy in <scp>D</scp>uchenne/<scp>B</scp>ecker muscular dystrophy. Annals of Neurology, 2014, 76, 541-549.	2.8	73
118	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Cardiac Sarcoidosis. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 230-236.	2.1	112
119	Mutations in AlstrÃ¶m protein impair terminal differentiation of cardiomyocytes. Nature Communications, 2014, 5, 3416.	5.8	66
120	A Pkd1-Fbn1 Genetic Interaction Implicates TGF-Î² Signaling in the Pathogenesis of Vascular Complications in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 81-91.	3.0	44
121	Exercise has a Disproportionate Role in the Pathogenesis of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in Patients Without Desmosomal Mutations. Journal of the American Heart Association, 2014, 3, e001471.	1.6	158
122	Identification of a New Modulator of the Intercalated Disc in a Zebrafish Model of Arrhythmogenic Cardiomyopathy. Science Translational Medicine, 2014, 6, 240ra74.	5.8	222
123	Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate With a Brugada Syndrome Phenotype. Circulation, 2014, 129, 1092-1103.	1.6	305
124	Yield of Serial Evaluation in At-Risk Family Members of Patients With ARVD/C. Journal of the American College of Cardiology, 2014, 64, 293-301.	1.2	88
125	Novel and Highly Lethal NKX2.5 Missense Mutation in a Family With Sudden Death and Ventricular Arrhythmia. Pediatric Cardiology, 2014, 35, 1206-1212.	0.6	26
126	Advances in Induced Pluripotent Stem Cells, Genomics, Biomarkers, and Antiplatelet Therapy Highlights of the Year in JCTR 2013. Journal of Cardiovascular Translational Research, 2014, 7, 518-525.	1.1	3

#	Article	IF	Citations
127	Transthyretin Cardiac Amyloidosis: Pathogenesis, Treatments, and Emerging Role in Heart Failure with Preserved Ejection Fraction. Clinical Medicine Insights: Cardiology, 2014, 8s1, CMC.S15719.	0.6	30
128	Mutationâ€Positive Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: The Triangle of Dysplasia Displaced. Journal of Cardiovascular Electrophysiology, 2013, 24, 1311-1320.	0.8	148
129	Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2013, 10, 1661-1668.	0.3	71
130	Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2013, 6, 1011-1020.	1.1	122
131	Malignant Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with a normal 12-lead electrocardiogram: A rare but underrecognized clinical entity. Heart Rhythm, 2013, 10, 1484-1491.	0.3	47
132	Exercise Increases Age-Related Penetrance and Arrhythmic Risk in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathyâ€“Associated Desmosomal Mutation Carriers. Journal of the American College of Cardiology, 2013, 62, 1290-1297.	1.2	553
133	LMNAâ€associated cardiocutaneous progeria: An inherited autosomal dominant premature aging syndrome with late onset. American Journal of Medical Genetics, Part A, 2013, 161, 1599-1611.	0.7	25
134	A family with a complex clinical presentation characterized by arrhythmogenic right ventricular dysplasia/cardiomyopathy and features of branchioâ€oculoâ€facial syndrome. American Journal of Medical Genetics, Part A, 2013, 161, 371-376.	0.7	9
135	Exercise Testing in Asymptomatic Gene Carriers Exposes a Latent Electrical Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of the American College of Cardiology, 2013, 62, 1772-1779.	1.2	64
136	Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovascular Pathology, 2013, 22, 189-194.	0.7	52
137	Incremental Value of Cardiac Magnetic Resonance Imaging in Arrhythmic Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathyâ€“Associated Desmosomal Mutation Carriers. Journal of the American College of Cardiology, 2013, 62, 1761-1769.	1.2	112
138	Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature, 2013, 494, 105-110.	13.7	474
139	Risk Stratification in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathyâ€“Associated Desmosomal Mutation Carriers. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 569-578.	2.1	94
140	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 1199-1207.	2.9	369
141	Outcomes of Catheter Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 499-505.	2.1	175
142	A Clinical Approach to a Family History of Sudden Death. Circulation: Cardiovascular Genetics, 2012, 5, 697-705.	5.1	6
143	Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2012, 9, 961-967.	0.3	56
144	Genetic Testing for Dilated Cardiomyopathy in Clinical Practice. Journal of Cardiac Failure, 2012, 18, 296-303.	0.7	145

#	Article	IF	Citations
145	The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 12.	1.6	141
146	Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal, 2012, 164, 222-228.e1.	1.2	209
147	Cardiac Transplantation in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2012, 59, 289-290.	1.2	76
148	The Complex Genetics of Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 1182-1184.	1.2	7
149	Multi-Scale Biomechanical Remodeling in Aging and Genetic Mutant Murine Mitral Valve Leaflets: Insights into Marfan Syndrome. PLoS ONE, 2012, 7, e44639.	1.1	18
150	Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Annals of Neurology, 2012, 71, 141-145.	2.8	49
151	Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. American Journal of Cardiovascular Drugs, 2011, 11, 287-294.	1.0	73
152	Cardiovascular genetics provides new insights for early onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2011, 8, 1696-1697.	0.3	1
153	Distinguishing Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasiaâ€“Associated Mutations From Background Genetic Noise. Journal of the American College of Cardiology, 2011, 57, 2317-2327.	1.2	269
154	Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary Prevention. Journal of the American College of Cardiology, 2011, 58, 1485-1496.	1.2	226
155	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm, 2011, 8, 1308-1339.	0.3	995
156	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	0.7	699
157	Reader- and Instrument-Dependent Variability in the Electrocardiographic Assessment of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2011, 22, 561-568.	0.8	8
158	Mitral Valve Disease in Marfan Syndrome and Related Disorders. Journal of Cardiovascular Translational Research, 2011, 4, 741-747.	1.1	45
159	The Mitral Valve in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2011, 4, 757-766.	1.1	30
160	Translational Research on the Mitral Valve: from Developmental Mechanisms to New Therapies. Journal of Cardiovascular Translational Research, 2011, 4, 699-701.	1.1	13
161	Noncanonical TGFÎ² Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice. Science, 2011, 332, 358-361.	6.0	422
162	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2011, 123, 2661-2663.	1.6	4

#	Article	IF	Citations
163	Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism. Science, 2011, 332, 361-365.	6.0	414
164	Shared Desmosome Gene Findings in Early and Late Onset Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Translational Research, 2010, 3, 663-673.	1.1	21
165	Use of Genetics in the Clinical Evaluation and Management of Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 566-577.	0.4	6
166	Response to Letters Regarding Article, â€œElectrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasiaâ€• Circulation, 2010, 121, .	1.6	1
167	One step closer to personalized genomic medicine. European Heart Journal, 2010, 31, 2194-2196.	1.0	0
168	Comprehensive Desmosome Mutation Analysis in North Americans With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation: Cardiovascular Genetics, 2009, 2, 428-435.	5.1	195
169	Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia. Circulation, 2009, 120, 477-487.	1.6	88
170	Familial Amyloid Cardiomyopathy Due to TTR Mutations: An underground Cause of Restrictive Cardiomyopathy. Journal of Cardiac Failure, 2009, 15, 464.	0.7	3
171	The Change in B-Type Natriuretic Peptide Levels Over Time Predicts Significant Rejection in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2009, 28, 704-709.	0.3	35
172	Use of Genetics in the Clinical Evaluation of Cardiomyopathy. JAMA - Journal of the American Medical Association, 2009, 302, 2471.	3.8	50
173	Morphologic Variants of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2009, 53, 1289-1299.	1.2	84
174	Prolonged RV endocardial activation duration: A novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2009, 6, 769-775.	0.3	32
175	Phenotypic diversity arising from a single mutation. Heart Rhythm, 2009, 6, 1584-1585.	0.3	3
176	Familial Hypertrophic Cardiomyopathy Associated with Cardiac Î²-Myosin Heavy Chain and Troponin I Mutations. Pediatric Cardiology, 2008, 29, 846-850.	0.6	21
177	Genetic Evaluation of Familial Cardiomyopathy. Journal of Cardiovascular Translational Research, 2008, 1, 144-154.	1.1	25
178	Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome. New England Journal of Medicine, 2008, 358, 2787-2795.	13.9	767
179	Mechanisms of Disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 258-267.	3.3	207
180	Therapy of Marfan Syndrome. Annual Review of Medicine, 2008, 59, 43-59.	5.0	56

#	Article	IF	Citations
181	E713K in desmoglein-2 and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, E2-E2.	3.3	0
182	Loss of Elastic Fiber Integrity and Reduction of Vascular Smooth Muscle Contraction Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in the Thoracic Aortic Aneurysm in Marfan Syndrome. Circulation Research, 2007, 101, 512-522.	2.0	193
183	Current treatment of adult Duchenne muscular dystrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 229-237.	1.8	120
184	Intracardiac Giant Cells After Left Ventricular Assist Device Placement. Journal of Heart and Lung Transplantation, 2007, 26, 417-420.	0.3	0
185	Extensive Cardiac Allograft Vasculitis and Concurrent Fat Necrosis 6 Years After Orthotopic Heart Transplantation. Journal of Heart and Lung Transplantation, 2007, 26, 1212-1216.	0.3	5
186	Heart Failure and Genomics. Journal of the American College of Cardiology, 2007, 49, 1106.	1.2	1
187	Long-Term Efficacy of Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 432-440.	1.2	236
188	Angiotensin II type 1 receptor blockade attenuates TGF-Î²â€“induced failure of muscle regeneration in multiple myopathic states. Nature Medicine, 2007, 13, 204-210.	15.2	603
189	Utility of Tissue Doppler and Strain Echocardiography in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. American Journal of Cardiology, 2007, 100, 507-512.	0.7	73
190	The benefit of upgrading chronically right ventricleâ€“paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm, 2006, 3, 435-442.	0.3	74
191	DSG2 Mutations Contribute to Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. American Journal of Human Genetics, 2006, 79, 136-142.	2.6	206
192	Penetrance of Mutations in Plakophilin-2 Among Families With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2006, 48, 1416-1424.	1.2	122
193	Use of a Coronary Sinus Lead and Biventricular ICD to Correct a Sensing Abnormality in a Patient with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2006, 17, 317-320.	0.8	15
194	Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation inPKP2. Human Mutation, 2006, 27, 1157-1157.	1.1	77
195	Clinical Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Associated With Mutations in Plakophilin-2. Circulation, 2006, 113, 1641-1649.	1.6	225
196	Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Science, 2006, 312, 117-121.	6.0	1,591
197	Toward an Understanding of Dural Ectasia: A Light Microscopy Study in a Murine Model of Marfan Syndrome. Spine, 2005, 30, 291-293.	1.0	50
198	A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature Genetics, 2005, 37, 275-281.	9.4	1,543

#	Article	IF	Citations
199	Conductance catheter-based assessment of arterial input impedance, arterial function, and ventricular-vascular interaction in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1157-H1164.	1.5	51
200	Arrhythmogenic Right Ventricular Dysplasia. Circulation, 2005, 112, 3823-3832.	1.6	434
201	Reversible cardiomyopathy caused by administration of interferon Î±. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 53-57.	3.3	30
202	Marfan's syndrome. Lancet, The, 2005, 366, 1965-1976.	6.3	1,021
203	Short-Term Effects of Right-Left Heart Sequential Cardiac Resynchronization in Patients With Heart Failure, Chronic Atrial Fibrillation, and Atrioventricular Nodal Block. Circulation, 2004, 110, 3404-3410.	1.6	120
204	Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 172-181.	3.9	319
205	TGF-Î²â€“dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 1586-1592.	3.9	467
206	Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 172-181.	3.9	225
207	TGF-Î²â€“dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 1586-1592.	3.9	303
208	KLOTHO Allele Status and the Risk of Early-Onset Occult Coronary Artery Disease. American Journal of Human Genetics, 2003, 72, 1154-1161.	2.6	225
209	Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?. Human Molecular Genetics, 2003, 12, 2269-2276.	1.4	110
210	Characterization of microsatellite markers flankingFBN1: Utility in the diagnostic evaluation for Marfan syndrome. American Journal of Medical Genetics Part A, 2001, 99, 39-47.	2.4	12